Expert Perspectives in the Evolving ALK+ NSCLC Paradigm

Published: Tuesday, Mar 24, 2020
In a wide-ranging discussion, Alexander Drilon, MD; Julia Rotow, MD; Thomas E. Stinchcombe, MD; and Ashish Saxena, MD, PhD, provide expert insight on the latest groundbreaking developments in the evolving treatment landscape for patients with ALK-positive non–small cell lung cancer (NSCLC).

Alexander Drilon, MD, Alexander Drilon, MD, research director, Early Drug Development, Early Drug Development Service, Memorial Sloan Kettering Cancer Center

Alexander Drilon, MD

Drilon: Biomarker testing is critical in non–small cell lung cancers and in patients who have advanced disease. In the past, we only knew about sensitizing EGFR mutations and recurrent gene fusions, including ALK. Now we have several other mutations, fusions, and copy number changes that are actionable, as we say, meaning that patients can be matched and [receive] active targeted therapy; either 1 that’s approved by the FDA or other regulatory agencies or maybe 1 that’s in the NCCN [National Comprehensive Cancer Network] guidelines or already in clinical trials. Examples of these are BRAF V600E mutations, for which the dabrafenib/trametinib combination is approved, and RET fusions. We saw interesting data on selective RET inhibitors, MET exon 14 alterations, [and] NTRK fusions, for which we have a tumor agnostic approval for larotrectinib and entrectinib.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication